1Longley DB, Harkin DP, Johnston PG. 5-fluorouracil: mechanisms of action and clinical strategies. Nat Rev Cancer 2003; 3:330-338.
2Mitchell MS. Combinations of anticancer drugs and immunotherapy. Cancer Immunol Immunother 2003; 52- 686-692.
3Lau WY, Leung TW, Lai BS, Liew CT, Ho SK, Yu SC, Tang AM. Preoperative systemic chemoimmunotherapy and sequential resection for unresectable hepatocellular carcinoma. Ann Surg 2001; 233:236-241.
4Leung TW, Tang AM, Zee B, Yu SC, Lai PB, Lau WY, Johnson PJ. Factors predicting response and survival in 149 patients with unresectable hepatocellular carcinoma treated by combination cisplatin, interferon-alpha, doxorubicin and 5-fluorouracil chemotherapy. Cancer 2002; 94:421-427.
5Llovet JM, Bruix J. Systematic review of randomized trials for unresectable hepatocellular carcinoma: chemoembolization improves survival. Hepatology 2003; 37:429-442.
6Atzpodien J, Royston P, Wandert T, Reitz M. Metastatic renal carcinoma comprehensive prognostic system. Br J Cancer 2003; 88:348-353.
7Delannoy A, Cazin B, Thomas X, Bouabdallah R, Boiron JM,Huguet F, Straetmans N, Zerazhi H, Vernant JP, Dombret H,Bilhou-Nabera C, Charrin C, Boucheix C, Sebban C, Lheritier V, Fiere D. Treatment of acute lymphoblastic leukemia in the elderly: an evaluation of interferon alpha given as a single agent after complete remission. Leuk Lymphoma 2002; 43:75-81.
8Treiber G. Systemic treatment of hepatocellular carcinoma.Dig Dis 2001; 19:311-323.
9Hertzog PJ, O'Neill LA, Hamilton JA. The interferon in TLR signalling: more than just antiviral. Trends Immunol 2003; 24:534-539.
10Kaneko F, Saito H, Saito Y, Wakabayashi K, Nakamoto N,Tada S, Suzuki H, Tsunematsu S, Kumagai N, Ishii H. Downregulation of matrix-invasive potential of human liver cancer cells by type I interferon and a histone deacetylase inhibitor sodium butyrate. Int J Oncol 2004; 24:837-845.
